CSS
CLVS

Cubist Systematic Strategies’s Clovis Oncology, Inc. CLVS Stock Holding History

Cubist Systematic Strategies’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,367
Closed -$19K – 4982
2022
Q2 		$19K Sell
10,367
-13,772
-57% -$20.3K ﹤0.01% 4227
2022
Q1 		$49K Buy
24,139
+9,339
+63% +$18.3K ﹤0.01% 3386
2021
Q4 		$40K Sell
14,800
-2,067
-12% -$7.64K ﹤0.01% 3333
2021
Q3 		$75K Sell
16,867
-64,856
-79% -$312K ﹤0.01% 2790
2021
Q2 		$474K Sell
81,723
-107,567
-57% -$630K 0.01% 2052
2021
Q1 		$1.33M Buy
189,290
+185,377
+4,737% +$1.24M 0.02% 1334
2020
Q4 		$19K Sell
3,913
-21,115
-84% -$107K ﹤0.01% 2506
2020
Q3 		$146K Buy
25,028
+585
+2% +$3.5K ﹤0.01% 2215
2020
Q2 		$165K Buy
24,443
+12,546
+105% +$95K ﹤0.01% 2094
2020
Q1 		$76K Buy
+11,897
New +$95.4K ﹤0.01% 1951
2019
Q4 		– Sell
-296,953
Closed -$1.17M – 2604
2019
Q3 		$1.17M Buy
296,953
+152,688
+106% +$1.24M 0.02% 908
2019
Q2 		$2.15M Buy
144,265
+45,560
+46% +$823K 0.04% 648
2019
Q1 		$2.45M Buy
98,705
+88,367
+855% +$2.22M 0.08% 366
2018
Q4 		$186K Sell
10,338
-9,711
-48% -$198K 0.01% 1573
2018
Q3 		$589K Buy
+20,049
New +$776K 0.03% 729
2018
Q2 		– Sell
-5,784
Closed -$305K – 2132
2018
Q1 		$305K Buy
5,784
+4,660
+415% +$272K 0.02% 1141
2017
Q4 		$76K Buy
+1,124
New +$78.6K ﹤0.01% 1728
2017
Q3 		– Sell
-133
Closed -$12K – 2055
2017
Q2 		$12K Buy
+133
New +$8.14K ﹤0.01% 1620
2015
Q4 		– Sell
-20,900
Closed -$1.92M – 2017
2015
Q3 		$1.92M Sell
20,900
-2,482
-11% -$215K 0.1% 278
2015
Q2 		$2.06M Sell
23,382
-2,165
-8% -$185K 0.1% 262
2015
Q1 		$1.9M Buy
+25,547
New +$1.8M 0.09% 290
2014
Q4 		– Sell
-23,864
Closed -$1.08M – 2094
2014
Q3 		$1.08M Sell
23,864
-5,825
-20% -$243K 0.07% 433
2014
Q2 		$1.23M Buy
+29,689
New +$1.53M 0.07% 396

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cubist Systematic Strategies's CLVS Position: Q3 2022 in Review

Cubist Systematic Strategies sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 10,367 shares — an estimated $19K sold.

Cubist Systematic Strategies first reported a position in CLVS in Q2 2014 and held it in 23 quarters. The position peaked at $2.45M in Q1 2019. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

  • Cubist Systematic Strategies reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 10,367 Clovis Oncology, Inc. shares in Q3 2022, an estimated $19K.
  • Cubist Systematic Strategies first reported a position in Clovis Oncology, Inc. in Q2 2014 and held it in 23 quarters.
  • Cubist Systematic Strategies's Clovis Oncology, Inc. position peaked at $2.45M in Q1 2019.
  • 103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Cubist Systematic Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.